Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299714 · ClinicalTrials.gov registry record
Community Awareness, Resources and Education (CARE II): Project 3
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 191
- Enrollment target
NCT01299714: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01299714 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 191 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01299714 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and Drug Administration (FDA) to prevent some types of Human Papillomavirus (HPV) infection which can cause cancer of the cervix. Participants are being recruited from the Appalachian region of Ohio.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-04 |
What the finished NCT01299714 record still lists
NCT01299714 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01299714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01299714 about?
NCT01299714 is a clinical study titled "Community Awareness, Resources and Education (CARE II): Project 3". Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix. One of the areas they are studying is how stress you may experience in your life effects the way you respond to GARDASIL®. GARDASIL® is a vaccine approved by the Food and ...
What is the current status of trial NCT01299714?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2011-02. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01299714?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia